DUBLIN, Dec. 1, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/dhv9r5/global) has announced the addition of the "Global Recombinant Coagulation Factors Market Outlook: 2015-2020" report to their offering.
The global recombinant coagulation factors market has witnessed major growth over the past few years. The growth of this market is mainly due to increasing number of hemophilia patients, growing diagnosis rates, and rising number of research and development on coagulation factors. In addition, increasing prophylactic treatment for hemophilia across the globe is further expected to drive the growth of this market. However, high cost of hemophilia treatment and low cost plasma coagulation factor alternatives to recombinant coagulation factors are hampering the growth of this market. Many players are focusing on Asia Pacific region to expand their businesses as this market is most lucrative for the recombinant coagulation factors.
The global recombinant coagulation factors market is expected to reach around $9,939.7 million in 2020 and grow at a CAGR of 7.6% during the forecast period of 2015 to 2020. The global market is segmented on the basis of products, by hemophilia type, and geography. On the basis of product, recombinant coagulation factors market is segmented into three classes, namely, recombinant factor VIII, recombinant factor IX, and VonWillebrandfactor. By hemophilia type, global recombinant coagulation factors market is divided into hemophilia A and hemophilia B. By end user, global recombinant coagulation factors market is segmented into hospitals and clinics, research organizations, and academic institutes.
In 2014, the recombinant factor VIII accounted for the largest share of the global recombinant coagulation factor market. The large share of this segment can be attributed to increasing number of hemophilia A patients and rising prophylaxis treatment.
In 2014, North America dominated the market, with the largest share of 37.8%. The increasing number of hemophilia patients in the U.S., increasing diagnosis rates, and growing prophylactic treatment for prevention of bleeding helped the growth of this market. In addition, rising research on recombinant factor VIII is further expected to drive the growth of this market.
- Baxter International Inc
- Bayer AG
- Biogen Idec
- CSL Ltd.
- Grifols International SA
- Kedrion S.P.A.
- Novo Nordisk A/S
- Octapharma AG
- Pfizer Inc.
1 Introduction to Global Recombinant Coagulation Factors Market
2 Executive Summary
3 Market Insights
4 Global Recombinant Coagulation Factors- Market Crackdown ($ Value Analysis), By Type
5 Global Recombinant Coagulation Factors- Market Crackdown ($ Value Analysis), by hemophilia type
6 Global Recombinant Coagulation Factors- Market Crackdown ($ Value Analysis), by End user
7 Recombinant Coagulation Factors - Market Crackdown ($ Value Analysis, by Geography
8 Global Recombinant Coagulation Factors Market- Competitive Landscape
9 Company Profile
For more information visit http://www.researchandmarkets.com/research/dhv9r5/global
Laura Wood, +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets